[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Industrial Farmacéutica Cantabria, S.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100507556","phase-3-evaluation-of-efficacy-and-safety-of-oral-minoxidil-1-mg-in-female-androgenetic-alopecia-100507556",false,"NCT05888922","Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia","International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia","Inclusion Criteria:\n\n1. Female patients aged 18 years or older, with general good health (i.e., with no history of cardiovascular disorders, or any other clinically significant disease).\n2. Diagnosed with FAGA, based on a discernible decrease in hair density (Sinclair Scale 2-4) in the centroparietal area of the scalp.\n3. Hair color of patient provides sufficient contrast with the scalp and as confirmed by TrichoLab Virtual Tattoo® technology at Screening\u002FVisit 1.\n4. A personally signed and dated informed consent document indicating that the patient, has been informed of all pertinent aspects of the clinical trial.\n5. Negative serum pregnancy test at Visit 1\u002FScreening and negative urine pregnancy test at Visit 2\u002FBaseline for women of child-bearing potential (WOCBP).\n6. WOCBP must either be permanently sterile1 or agree to use a highly effective birth control method (failure rate ˂1% per year when used consistently and correctly) throughout the clinical trial and for at least 2 weeks after last administration of IPs.\n\n   Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2\u002FBaseline and if used as contraceptive and planned to be continued throughout the clinical trial duration.\n7. Patients willing to maintain the same hairstyle (color and hair regimen) throughout the clinical trial. Hair length must remain of sufficient length to not affect determination of hair density and patient should discuss with clinical trial personnel before changing from Visit 2\u002FBaseline.\n8. Patient is willing to maintain the same depilatory habits and intervals regarding facial or body hair before each visit throughout duration of the clinical trial.\n9. Patient is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical trial procedures, including daily e diary recordings by the patient using an own electronic device (e.g., tablet, smartphone, personal computer) and an internet connection during the clinical trial.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or known allergy to minoxidil or to any of the other components of the products.\n2. Pregnancy or pregnancy desire during the clinical trial.\n3. Breastfeeding\u002FNursing women.\n4. Any diagnosed treated or untreated hypertension (or blood pressure values \\>150 mmHg systolic \u002F \\>95 mmHg diastolic) as determined at Visit 1\u002FScreening, and\u002For history\u002Fsigns of known cardiovascular diseases (including but not limited to cardiac ischemia, congestive heart failure, cardiac arrhythmia), and patients with pathologies or punctual situations that might either be caused by or increase the risk of cardiac disorders.\n5. Patients with any dermatological disorders of the scalp in the target region at Visit 1\u002FScreening with the possibility of interfering with the application of the IPs or examination method, such as\n\n   1. Active moderate or severe seborrheic dermatitis under chronic treatment, abrasion, actinic keratosis, or inflammatory disorders, or\n   2. any local infection of the skin\u002Fsubcutaneous tissues of the head within the previous 3 months, or\n   3. any documented history of active atopic dermatitis or psoriasis in the scalp within the previous 6 months.\n   4. any other types of alopecia (e.g., alopecia areata or scarring alopecia) at any time point or diffuse telogen effluvium, trichotillomania, or other pathological hair loss conditions\u002Fdiseases other than AGA in the last 3 months at the discretion of the investigator).\n6. Patients who had hair transplant surgery at any time.\n7. Patients who had hair weaving, or any other hair extension methods within the last 6 months prior to Visit 2\u002FBaseline.\n8. Clinically significant abnormal laboratory values or ECG findings (if applicable) at Visit 1\u002FScreening indicative of physical illness, according to investigator assessment.\n9. Both creatinine and eGFR above upper limit of normal at Visit 1\u002FScreening.\n10. Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases that in the opinion of the investigator may interfere with the aim of the clinical trial.\n11. Patient has used any of the following topical preparations or procedures on the scalp:\n\n    1. Topical scalp treatments for hair growth, including minoxidil within the last 6 months prior to Visit 2\u002FBaseline; or hormone therapy, antiandrogens, or other agents that are known to affect hair growth within 12 weeks prior to Visit 2\u002FBaseline.\n    2. Topical scalp treatments that might have had ancillary effect on hair growth including, but not limited to, corticosteroids, pimecrolimus, and tacrolimus within the last 4 weeks prior to Visit 2\u002FBaseline.\n    3. Topical scalp over the counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Maxilene®, Nioxin®, Foltene®, etc.) or hair health or hair growth products with saw palmetto, copper, etc. within the last 4 weeks prior to Visit 2\u002FBaseline.\n    4. Light or laser treatment or microneedling of scalp within the last 6 months prior to Visit 2\u002FBaseline.\n    5. Platelet rich plasma (PRP) procedure on the scalp within the last 6 months prior to Visit 2\u002FBaseline.\n12. Patient has used the following systemic medications or procedures:\n\n    1. Zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine, benoxaprofen, tamoxifen, phenothiazines, or other vasodilators or antihypertensive agents such as guanethidine and derivatives within the last 12 months prior to Visit 2\u002FBaseline.\n    2. Any 5 alpha reductase medications (i.e., dutasteride, finasteride \\[Propecia®, etc.\\] or similar product\\[s\\]) within the last 12 months prior to Visit 2\u002FBaseline.\n    3. Retinoid therapy within the last 6 months prior to Visit 2\u002FBaseline.\n    4. Beta blockers, anabolic steroids, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2\u002FBaseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable (defined as doses and frequency unchanged for at least 4 weeks prior to Visit 2\u002FBaseline.\n    5. Drugs with antiandrogenic properties, such as flutamide, cimetidine, or ketoconazole within the last 6 months prior to Visit 2\u002FBaseline; bicalutamide within 2 months and spironolactone within 1 month prior to Visit 2\u002FBaseline. Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2\u002FBaseline and if used as contraceptive.\n    6. Minoxidil within the last 6 months prior to Visit 2\u002FBaseline.\n    7. Prostaglandins and derivates within the last 3 months prior to Visit 2\u002FBaseline. Topical and ocular prostaglandins and its derivates are allowed.\n    8. Biotin (\\>5 mg) within the last 4 weeks prior to Visit 2\u002FBaseline.\n    9. Previous radiation of the scalp and treatment with chemotherapy\u002Fsystemic cytotoxic agents at any timepoint.\n13. Participation in the evaluation of any investigational drugs within 30 days or 5 half lives (whichever is longer) prior to Visit 2\u002FBaseline, calculated from the first day of the month following the last visit of the previous clinical trial.\n14. History of drug and alcohol dependency.\n15. In the opinion of the investigator the patient should not participate in the clinical trial, e.g., due to probable non compliance or inability to understand the clinical trial and give adequately informed consent.\n16. Close affiliation with the investigator (e.g., a close relative) or persons working at the clinical trial centers or patient is an employee of sponsor.\n17. Patient is institutionalized because of legal or regulatory order.","FEMALE","18 Years",{"count":19,"type":20},520,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss.\n\nThe main questions to answer are to know about that minoxidil 1mg is as effective as minoxidil 2% topical solution (comparator product) and is more effective than placebo; and to ensure treatment with oral minoxidil is safe.\n\nParticipants will be assigned randomly to receive one of the following treatment combinations:\n\n* the test product (oral minoxidil 1 mg, once\u002Fday) and the vehicle solution (vehicle means it looks like the comparator product, but it does not contain an active ingredient, 2 times\u002Fday), or\n* the placebo tablet (placebo means it looks like the test product, but it does not contain an active ingredient, once\u002Fday) and the comparator product (2% minoxidil solution, 2 times\u002Fday), or\n* the placebo tablet (once\u002Fday) and the vehicle solution (2 times\u002Fday).\n\nThe clinical trial will take up to 36 weeks. During this time, patients will come to the clinical trial centre for 5 times for examinations and will be called by phone twice. At the visits, the following examinations will be performed: photos of the hair will be taken to determine hair density, assessment of changes in scalp hair growth, measurement of blood pressure, pulse, and body temperature, a physical examination, blood withdrawal to determine any abnormalities in the blood, urine sampling and analysis, performance of ECG, and evaluation of hypertrichosis (i.e., excessive hair growth over the body). Furthermore, patients will be asked daily whether they had experienced any side effects or took any new medications (or changed the dose of a known medication) or underwent any medical procedure. Also, women of childbearing potential must undergo pregnancy tests in blood and urine.",[26,27],"Androgenetic Alopecia","Female Pattern Baldness",[29,27,30,31],"Androgenetic alopecia","FAGA","Minoxidil","RECRUITING","2026-05-08",{"date":35,"type":36},"2026-05-12","ACTUAL",{"date":38,"type":36},"2024-10-17",{"date":40,"type":20},"2026-11",{"name":42,"class":43},"Industrial Farmacéutica Cantabria, S.A.","INDUSTRY",13,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100528237","a-pilot-study-to-evaluate-the-systemic-effect-of-oral-supplementation-with-am3-in-patients-with-metabolic-syndrome-100528237","NCT06158152","A Pilot Study to Evaluate the Systemic Effect of Oral Supplementation With AM3 in Patients With Metabolic Syndrome.","A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.","Inclusion Criteria:\n\n1. Men or women aged 18-75 years at the time of signing the informed consent form.\n2. Diagnosis of metabolic syndrome, defined as: central obesity, elevation of blood glucose by ≥100 mg\u002Fdl, glycosylated hemoglobin between 5.7 and 6.4%, low HDL cholesterol levels \\\u003C 40 mg\u002Fdl in men and \\\u003C 50 mg\u002Fdl in women, and high levels of triglycerides, being higher than 150 mg\u002Fdl.\n3. If the patient is being treated with metformin, lipid-lowering treatment with statins or treatment with antihypertensives, he\u002Fshe must have a stable dose at the time of inclusion.\n\nExclusion Criteria:\n\n1. Smokers or with history of alcoholism or drug abuse .\n2. To have hypertriglyceridemia (\\> 500 mg\u002FdL).\n3. Uncontrolled arterial hypertension, as per investigator's criteria.\n4. To have undergone bariatric surgery over the last 24 months that according to investigator's criteria, this might interfere with his\u002Fher participation in the study.\n5. Diagnosis of chronic diseases that according to investigator's criteria, this might interfere with his\u002Fher participation in the study.\n6. Presence of renal insufficiency (glomerular filtration rate below 30 ml\u002Fminute).\n7. Presence of severe respiratory insufficiency (PaO2 less than 60 mmHg or PaCO2 greater than 50 mmHg).\n8. Presence of heart failure (LVEF \\\u003C30% and RVEF \\\u003C35%).\n9. Presence of the following diseases in an unstable manner, according to the investigator's criteria: chronic obstructive disease, inflammatory bowel disease, intestinal malabsorption syndrome, systemic autoimmune diseases, rheumatoid arthritis, spondyloarthritis, psoriasis, and chronic inflammatory skin diseases.\n10. Active or chronic severe unstable infections that, in medical criteria, may interfere with patients' safety.\n11. Disease-related malnutrition.\n12. Endocrinologic unestable or uncontrolled diseases that in medical criteria, present with manifestations in pituitary, adrenal or thyroid function.\n13. Immunosuppressive or corticosteroid treatment in the last 3 months.\n14. Treatment with semaglutide and tirzepatide.\n15. Pregnant women (or intending to become pregnant) or breast-feeding women.","ALL","75 Years",{"count":55,"type":20},48,[57],"NA","The goal of this pilot study is to learn about the effect of the nutritional supplementation based on AM3 in combination with probiotics on imflammatory and metabolic mediators in adult subjects diagnosed with metabolic syndrome.\n\nThe hypothesis the investigators are testing focuses on the fact that the continued use of the nutritional supplement with AM3 and probiotics is capable of minimizing the risk factors associated with metabolic syndrome, by reducing the development of the derived chronic pathologies.\n\nA total of 48 subjects with a diagnosis of metabolic syndrome is planned to be recruited from two investigational sites in the Comunity of Madrid (Spain). These subjects will be randomized into three treatment groups (active, placebo, and control). The dosage will be of 2 capsules\u002Fday in a single intake in the morning for 12 weeks. Two interventional visits are planned to be performed: at baseline and at week 12.",[60],"Metabolic Syndrome",[60,62,63,64,65,66],"AM3","Probiotics","Inmunoferon","Food suplement","Immune response","2025-06-23",{"date":69,"type":36},"2025-06-26",{"date":71,"type":36},"2024-05-20",{"date":73,"type":20},"2026-03-01",{"name":42,"class":43},2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":75},"100580757","six-month-single-blind-placebo-controlled-study-of-a-dietary-supplement-supplement-on-hair-growth-in-45-volunteers-100580757","NCT06841458","Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers","Instrumental, Single-Blind, Placebo-Controlled Study Evaluating the Efficacy of a Dietary Supplement on Hair Growth Over 6 Months in 45 Volunteers","Inclusion Criteria:\n\n* Written consent for LOPD compliance.\n* Written informed consent for study DC.506.36.117.\n* Gender: Male.\n* Age: Between 18 and 45 years.\n* Diagnosis of alopecia with low hair density, classified as mild to moderate (stages II, III, and IV on the Hamilton-Norwood scale).\n\nWillingness to have a 1-2 cm² area shaved throughout the study period.\n\n* Last participation in a clinical study on hair health must have ended at least six months before the start of this study.\n* 30-day washout period without specific hair treatments (using a neutral shampoo).\n* No use of any other topical or oral hair treatments in the target area during the study period; if necessary, consultation with the principal investigator is required to evaluate continued study participation.\n\nExclusion Criteria:\n\n* Individuals with gastrointestinal diseases (e.g., diabetes, gastritis, Crohn's disease, celiac disease, ulcers, intolerances, etc.).\n* Individuals with other physiological disorders (e.g., diabetes, hypertension, dyslipidemia) and\u002For gallstones.\n* Individuals undergoing medical treatment in the weeks prior to the study that may interfere with study assessments (as determined by the investigator), particularly those who are currently taking or have taken 5α-reductase inhibitors (Finasteride, Dutasteride, Minoxidil, etc.) within the last three months.\n\nIndividuals who have undergone hair restoration treatments at any point in their lives, including hair transplants, mesotherapy, or platelet-rich plasma (PRP) therapy.\n\n* Individuals following an atypical diet or planning to change their dietary routine during the study period.\n* Individuals enrolled in another clinical study with similar characteristics (as determined by the investigator) during the study period.\n* Individuals who are unable to fully understand the informed consent document or adhere to the study protocol.","MALE","45 Years",{"count":86,"type":20},45,[57],"This clinical study is designed to evaluate the efficacy and safety of a dietary supplement CL-P24113a for the management of androgenetic alopecia (AGA) in male subjects aged 18 to 45 years who suffer from alopecia with low hair density, classified as mild to moderate (Hamilton-Norwood stages II, III, and IV). The product is a formulation based on a blend of botanical ingredients and other well-established compounds, including Pumpkin Seed Oil (Curcubita pepo), Saw Palmetto Oil (Serenoa repens), L-Cystine, Prunus africana Bark Extract (Pygeum africanum), Horsetail Extract (Equisetum arvense), Olive Leaf Extract, among other excipients. These components have a well-documented history of safe use in both topical and oral applications with supporting safety information from international bodies such as EFSA. In this instrumental, single-blind, placebo-controlled study, 45 volunteers will be divided into two groups, with 30 subjects receiving the supplement and 15 subjects receiving a placebo. All participants will ingest one capsule per day, preferably in the morning with a glass of water, over a 6-month treatment period. Prior to study initiation, subjects must complete a 30-day washout period using a neutral shampoo and agree not to apply any other topical or oral hair treatments in the target area throughout the study. The study will evaluate efficacy through both instrumental and subjective assessments. Instrumental evaluations will be conducted at 3 and 6 months using the TrichoScan HD Professional 4.0 system to measure hair growth parameters such as total hair count, hair density per cm², proportion of hairs, terminal hair count and density, proportion of terminal hairs, as well as the percentages of anagen and telogen hairs. Additionally, measurements of hair thickness including hair mass per cm², median and mean hair thickness in micrometers, overall scalp hair density, and median hair length will be recorded. Subjective evaluations will be performed via questionnaires administered at 1.5, 3, 4.5, and 6 months to capture participants' perceptions regarding hair growth and hair loss. The study is overseen by Principal Investigator at Dermaclaim Lab S.L. Regulatory compliance will be ensured by obtaining written informed consent for both study participation and data protection, and all subjects will be thoroughly briefed on study requirements and potential risks. This study aims to provide robust clinical evidence on the effectiveness of the oral supplement in promoting hair growth and reducing hair loss in men affected by androgenetic alopecia, potentially offering a safe and well-tolerated alternative to existing hair loss therapies while ensuring continuous monitoring for any adverse events throughout the treatment period.",[26],[91,26,92,93,94,95],"MAGA","Natural supplement","Saw Palmetto","Cucurbita Pepo","Alopecia","2025-02-21",{"date":98,"type":36},"2025-02-24",{"date":100,"type":36},"2024-10-07",{"date":102,"type":20},"2025-06-01",{"name":42,"class":43},""]